科研之友
微信
新浪微博
Facebook
分享链接
摘要
To the Editor: In their Perspective article, Morain et al. (Aug. 8 issue)(1) say that commercial companies have not met reasonable standards for demonstrating clinical validity. This is not correct. In five independent cohorts, researchers have examined 463 pregnancies with fetuses with Down's syndrome, 187 with trisomy 18, and 37 with trisomy 13. To maximize confidence in sensitivity estimates, all were high-risk pregnancies (in a general population, more than 250,000 pregnancies would have had to be studied). Five professional organizations, including the American Congress of Obstetricians and Gynecologists,(2) recommend offering such testing for high-risk pregnancies. The Perspective article also implies ...
- 出版日期2013-11-28
